Silverback Therapeutics, Inc.
https://silverbacktx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Silverback Therapeutics, Inc.
Capstan Launches, Backed By Big Names And Big Pharma, To Pioneer In Vivo Cell Therapies
The start-up, founded on science from the University of Pennsylvania, announced a $102m series A financing and the appointment of former Silverback CEO Laura Shawver as CEO.
Deal Watch: Cidara Licenses US Rights To Antifungal Under FDA Review To Melinta
Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.
BIO 2022 Notebook: Staying Afloat In Rough Waters
News and views from day two of the BIO annual meeting include reflections on the ups and downs of the financing environment, Cerevance CEO Craig Thomson on the challenges of raising VC funds right now, and Bayer business development exec Marianne de Backer explains that it's not a good strategy to buy things just because they are on sale.
BIO 2022 Notebook: Staying Afloat In Rough Waters
News and views from day two of the BIO annual meeting include reflections on the ups and downs of the financing environment, Cerevance CEO Craig Thomson on the challenges of raising VC funds right now, and Bayer business development exec Marianne de Backer explains that it's not a good strategy to buy things just because they are on sale.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- ARS Pharmaceuticals, Inc.